{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:45:20Z","timestamp":1784357120820,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jval.2024.07.015","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:21:22Z","timestamp":1723166482000},"page":"1698-1709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom"],"prefix":"10.1016","volume":"27","author":[{"given":"Osvaldo Ulises","family":"Garay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa Elena","family":"Amb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Walkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2024.07.015_bib1","author":"Ferlay"},{"issue":"2","key":"10.1016\/j.jval.2024.07.015_bib2","article-title":"Primary liver cancer in the UK: incidence, incidence-based mortality, and survival by subtype, sex, and nation","volume":"3","author":"Burton","year":"2021","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.jval.2024.07.015_bib3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/apt.13961","article-title":"Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study","volume":"45","author":"West","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.jval.2024.07.015_bib4","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v25.i13.1550","article-title":"Hepatocellular carcinoma surveillance: an evidence-based approach","volume":"25","author":"Harris","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jval.2024.07.015_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"J\u00a0Hepatocell Carcinoma"},{"key":"10.1016\/j.jval.2024.07.015_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101969","article-title":"Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database","volume":"59","author":"Liao","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"34","key":"10.1016\/j.jval.2024.07.015_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11340","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis","volume":"11","author":"Thompson Coon","year":"2007","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3350\/cmh.2019.1001","article-title":"Hepatocellular carcinoma surveillance in the 21st century: saving lives or causing harm?","volume":"25","author":"Hanouneh","year":"2019","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2022.08.036","article-title":"Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era?","volume":"78","author":"Parikh","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jval.2024.07.015_bib12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/lt.25398","article-title":"Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program","volume":"25","author":"Konerman","year":"2019","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.jval.2024.07.015_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/apt.14013","article-title":"Editorial: is surveillance for hepatocellular carcinoma really required for all British cirrhotics?","volume":"45","author":"Brennan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cgh.2011.06.004","article-title":"Surveillance for hepatocellular carcinoma in patients with cirrhosis","volume":"10","author":"Yang","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jval.2024.07.015_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1055-9965.EPI-11-1005","article-title":"Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"21","author":"Singal","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"10.1016\/j.jval.2024.07.015_bib17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2214\/AJR.21.26735","article-title":"Associations of ultrasound LI-RADS visualization score with examination, sonographer, and radiologist factors: retrospective assessment in over 10,000 examinations","volume":"218","author":"Fetzer","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/apt.13841","article-title":"Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"45","author":"Simmons","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jval.2024.07.015_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/hep.13.22","article-title":"Limitations of screening for hepatocellular carcinoma","volume":"1","author":"Sherman","year":"2014","journal-title":"Hepatic Oncol"},{"issue":"2","key":"10.1016\/j.jval.2024.07.015_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jval.2024.07.015_bib21","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/cells9061370","article-title":"Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment","volume":"9","author":"Pinero","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib22","first-page":"949","article-title":"The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"12","author":"Guan","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"Johnson","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib24","article-title":"SAT597 - a comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort","volume":"77","author":"Chan","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jval.2024.07.015_bib25","article-title":"Poster abstract: GAAD and GALAD algorithmic scores demonstrate equivalent clinical performance for hepatocellular carcinoma (HCC) surveillance in prospective, multicenter, case-control studies. WorldLab \u2022 EuroMedLab Roma","volume":"61","author":"Hou","year":"2023","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.jval.2024.07.015_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156801","article-title":"Alpha-fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection","volume":"11","author":"Bird","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jval.2024.07.015_bib27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/gut.2004.058636","article-title":"Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999","volume":"54","author":"Roberts","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib28","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jval.2024.07.015_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jval.2024.07.015_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.7861\/clinmedicine.15-2-139","article-title":"Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does alpha-fetoprotein still have a role?","volume":"15","author":"Webb","year":"2015","journal-title":"Clin Med (Lond)"},{"issue":"4","key":"10.1016\/j.jval.2024.07.015_bib31","doi-asserted-by":"crossref","first-page":"338.e11","DOI":"10.1016\/j.crad.2016.10.019","article-title":"Ultrasound surveillance for hepatocellular carcinoma: service evaluation of a radiology-led recall system in a tertiary-referral centre for liver diseases in the UK","volume":"72","author":"Farrell","year":"2017","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"issue":"11-12","key":"10.1016\/j.jval.2024.07.015_bib33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1365-2036.2010.04473.x","article-title":"The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study","volume":"32","author":"Fleming","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jval.2024.07.015_bib34","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1524-4733.2010.00782.x","article-title":"Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B","volume":"13","author":"Dakin","year":"2010","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"21","key":"10.1016\/j.jval.2024.07.015_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261619","article-title":"Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma","volume":"17","author":"Kondo","year":"2022","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jval.2024.07.015_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000317","article-title":"Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies","volume":"7","author":"Piratvisuth","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jval.2024.07.015_bib39","author":"Huang"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/liv.13555","article-title":"Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue","volume":"38","author":"Zhao","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2024.07.015_bib45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology","volume":"73","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jval.2024.07.015_bib46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cgh.2016.07.033","article-title":"Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance","volume":"15","author":"Khalaf","year":"2017","journal-title":"Clin Gastroenterol Hepatol Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jval.2024.07.015_bib47","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/jgh.13761","article-title":"Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: experience from a German referral center","volume":"32","author":"Kirstein","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jval.2024.07.015_bib48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: a systematic review","volume":"28","author":"McLernon","year":"2008","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2214\/AJR.18.20341","article-title":"Cost-utility analysis of imaging for surveillance and diagnosis of hepatocellular carcinoma","volume":"213","author":"Lima","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1572-0241.2003.07327.x","article-title":"Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis","volume":"98","author":"Arguedas","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/13651820600994541","article-title":"A\u00a0cost-utility analysis of treatments for malignant liver tumours: a pilot project","volume":"9","author":"McKay","year":"2007","journal-title":"HPB (Oxf)"},{"issue":"7","key":"10.1016\/j.jval.2024.07.015_bib53","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.dld.2016.03.031","article-title":"Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma","volume":"48","author":"Cucchetti","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib54","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.26221","article-title":"Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma","volume":"57","author":"Camma","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jval.2024.07.015_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18070","article-title":"The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation","volume":"18","author":"Loveman","year":"2014","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2024.07.015_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JHC.S144068","article-title":"Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"4","author":"Fateen","year":"2017","journal-title":"J\u00a0Hepatocell Carcinoma"},{"issue":"7616","key":"10.1016\/j.jval.2024.07.015_bib60","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.39308.560069.BE","article-title":"NICE\u2019s cost effectiveness threshold","volume":"335","author":"Appleby","year":"2007","journal-title":"Br Med J"},{"issue":"9","key":"10.1016\/j.jval.2024.07.015_bib61","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14737167.2021.1973892","article-title":"Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)","volume":"22","author":"Muszbek","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2024.07.015_bib63","first-page":"10","article-title":"Hepatocellular carcinoma surveillance: current practice and future directions","volume":"8","author":"Ahn","year":"2022","journal-title":"Hepatoma Res"},{"issue":"7","key":"10.1016\/j.jval.2024.07.015_bib64","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6604301","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis","volume":"98","author":"Thompson Coon","year":"2008","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.jval.2024.07.015_bib65","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2020.05.043","article-title":"Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis","volume":"73","author":"Jepsen","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cgh.2022.03.015","article-title":"The natural history of advanced chronic liver disease defined by transient elastography","volume":"21","author":"Shearer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2024.07.015_bib67","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jval.2024.07.015_bib68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.07.015_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jval.2024.07.015_bib70","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41416-021-01509-4","article-title":"Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England","volume":"126","author":"Burton","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jval.2024.07.015_bib71","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32434","article-title":"Risk factors for HCC in contemporary cohorts of patients with cirrhosis","volume":"77","author":"Kanwal","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jval.2024.07.015_bib72","first-page":"465","article-title":"The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: a Swedish nationwide population-based cohort study","volume":"10","author":"Bengtsson","year":"2022","journal-title":"U\u00a0Eur Gastroenterol J"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:46:02Z","timestamp":1733129162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1098301524027980"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.015","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}